B-Receptor Signaling in Cardiomyopathy
Public ClinicalTrials.gov record NCT01135849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.
Study identification
- NCT ID
- NCT01135849
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 99 participants
Conditions and interventions
Conditions
- Carcinomas
- Amyloidosis
- Anal Cancer
- Anemia
- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Transitional Cell Carcinoma of Bladder
- Bone Marrow Transplant Failure
- Bone Cancer
- Cancer of Brain and Nervous System
- Breast Cancer
- Carcinoma of the Large Intestine
- Endocrine Cancer
- Esophageal Cancer
- Eye Cancer
- Gall Bladder Cancer
- Gastric (Stomach) Cancer
- Gastrooesophageal Cancer
- Gastrointestinal Stromal Tumor (GIST)
- Gynecologic Cancers
- Head and Neck Cancers
- Hepatobiliary Neoplasm
- Kidney (Renal Cell) Cancer
- Leukemia
- Lung Cancer
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Mesothelioma
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Neuroendocrine Tumors
- Myeloproliferative Disorders
- Pancreatic Cancer
- Prostate Cancer
- Skin Cancer
- Soft Tissue Sarcoma
- Testicular Cancer
- Thymus Cancer
- Thyroid Cancer
Interventions
Not listed
Eligibility (public fields only)
- Age range
- Up to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2008
- Primary completion
- Sep 30, 2010
- Completion
- Sep 30, 2010
- Last update posted
- Nov 16, 2015
2008 – 2010
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01135849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2015 · Synced Sep 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01135849 live on ClinicalTrials.gov.